Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and BioMarin Pharmaceutical (BMRN)

Tipranks - Tipranks - Wed Feb 25, 9:08AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aclaris Therapeutics (ACRS – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Aclaris Therapeutics (ACRS)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aclaris Therapeutics today and set a price target of $16.00. The company’s shares closed last Tuesday at $3.39.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 23.3% and a 56.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, Reviva Pharmaceuticals Holdings, and Aardvark Therapeutics, Inc. ;'>

Currently, the analyst consensus on Aclaris Therapeutics is a Strong Buy with an average price target of $11.33.

See today’s best-performing stocks on TipRanks >>

BioMarin Pharmaceutical (BMRN)

Wedbush analyst Yun Zhong reiterated a Buy rating on BioMarin Pharmaceutical today and set a price target of $94.00. The company’s shares closed last Tuesday at $62.47, close to its 52-week low of $60.63.

According to TipRanks.com, Zhong is ranked 0 out of 5 stars with an average return of -6.3% and a 44.0% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, CAMP4 Therapeutics Corporation, and MoonLake Immunotherapeutics. ;'>

Currently, the analyst consensus on BioMarin Pharmaceutical is a Moderate Buy with an average price target of $86.20, a 43.0% upside from current levels. In a report issued on February 12, Jefferies also maintained a Buy rating on the stock with a $113.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).